<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773096</url>
  </required_header>
  <id_info>
    <org_study_id>MNTX-2013</org_study_id>
    <nct_id>NCT01773096</nct_id>
  </id_info>
  <brief_title>Methylnaltrexone Use for Opioid-induced Postoperative Constipation</brief_title>
  <official_title>The Use of Methylnaltrexone to Reduce Post-operative Opioid-induced Constipation in the Pediatric Spinal Fusion Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the routine use of methylnaltrexone in the
      post-operative pediatric spinal fusion patient will decrease the incidence of constipation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methylnaltrexone will be given to pediatric patients post-operative from spinal fusion
      surgery on post-operative day number 3 and then again on postoperative day number 4, if no
      laxation achieved. Various outcome measures, safety and efficacy of the drug will be observed
      and recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction of post-operative opioid induced constipation</measure>
    <time_frame>first post-operative week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to ambulation in post-operative pediatric spinal fusion patients</measure>
    <time_frame>first post-operative week</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>time to oral intake of pediatric post-operative spinal fusion patient</measure>
    <time_frame>first post-operative week</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Institutional bowel protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylnaltrexone</intervention_name>
    <description>Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Relistor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax</intervention_name>
    <description>Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.</description>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_label>Institutional bowel protocol</arm_group_label>
    <other_name>Senokot,Colace, Dulcolax, Milk of Magnesia, polyethylene glycol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  spinal fusion surgery

          -  current opioid use

          -  12 years of age and older

          -  no or inadequate bowel movement by post-operative day 3

        Exclusion Criteria:

          -  known or expected mechanical bowel obstruction

          -  known or suspected lesions of the GI tract

          -  unexpected transfer to ICU

          -  unexpected return to the operating room

          -  patient or parent refusal of methylnaltrexone

          -  incomplete data concerning time to laxation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah J. Vermaire, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospitals for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Hospitals for Children- Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Anissian L, Schwartz HW, Vincent K, Vincent HK, Carpenito J, Stambler N, Ramakrishna T. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med. 2012 Feb;7(2):67-72. doi: 10.1002/jhm.943. Epub 2011 Oct 13.</citation>
    <PMID>21998076</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shriners Hospitals for Children</investigator_affiliation>
    <investigator_full_name>Deborah J. Vermaire MD</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>opioid-induced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Bisacodyl</mesh_term>
    <mesh_term>Polyethylene glycol 3350</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
    <mesh_term>Magnesium Hydroxide</mesh_term>
    <mesh_term>Methylnaltrexone</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 17, 2016</submitted>
    <returned>October 7, 2016</returned>
    <submitted>October 12, 2016</submitted>
    <returned>December 2, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

